Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab + pomalidomide + dexamethasone versus pomalidomide + dexamethasone in relapsed and refractory multiple myeloma
NL-OMON50598Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elotuzumab, pomalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival. Started Jul 2016; status: completed.
02
Drugs
elotuzumabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON50598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50598.